Farxiga patent expiry?

When does the Farxiga patent expire?

Farxiga (dapagliflozin) is a medication used to treat type 2 diabetes and, in some cases, heart failure. It is developed by AstraZeneca, a global pharmaceutical company. The patent for Farxiga was granted in 2007 and is set to expire in 2025 for the original formulation, but the company has received several extensions due to ongoing research and developments in the field [1].

What impact does patent expiry have on the availability of Farxiga?

When the patent for Farxiga expires, other pharmaceutical companies may be able to create generic or biosimilar versions of the medication, which can increase competition and potentially lower the price. However, the actual impact of patent expiry on the availability and pricing of Farxiga depends on various factors, including regulatory approvals and market dynamics.

How does patent expiry affect AstraZeneca's revenue?

AstraZeneca has reported that it will continue to face competition from generic alternatives to Farxiga after the patent expiry, which may lead to a decrease in sales and revenue. The company has stated that it is working to maintain its market share through the use of its branded products, including its own generic or authorized version of Farxiga [2].

What can patients expect?

Patients who are currently using Farxiga may not be significantly affected by the patent expiry. However, they may need to consult with their healthcare providers to determine the best course of treatment if their insurance companies start to cover generic versions of the medication.

Sources:

[1] AstraZeneca. (2020). AstraZeneca to Present Data on Farxiga at the 56th ERA-EDTA Congress. Retrieved from https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-to-present-data-on-farxiga-at-the-56th-era-edta-congress.html

[2] AstraZeneca. (2022). AstraZeneca's Q4 and full-year 2022 results. Retrieved from https://www.astrazeneca.com/investors/results-releases/2023/2022-fourth-quarter-report.html

For more information on Farxiga and its patent status, please refer to DrugPatentWatch.com [3] [4].

Sources:

[3] DrugPatentWatch.com. (2023). Farxiga (Dapagliflozin). Retrieved from https://www.drugpatentwatch.com/drugs/farxiga-dapagliflozin/

[4] AstraZeneca. (2023). Farxiga USPI. Retrieved from https://www.astrazeneca-us.com/product/pi/FARXIGAuspinov_2022.pdf